Sponsored Links

 

Displaying saxagliptin PowerPoint Presentations



Saxagliptin Assessment of Vascular Outcomes Recorded in ... PPT

Presentation Summary : Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR) – TIMI 53. Deepak L. Bhatt, MD, MPHOn behalf of the SAVOR-TIMI 53 ...

Source : http://www.cardiosource.org/~/media/Files/Science%20and%20Quality/Clinical%20Trials/ESC%2013%20Slides/SAVOR-TIMI%2053%20Presentation%20Slides.ashx

Incretin Based Therapy of Type 2 Diabetes Mellitus PPT

Presentation Summary : ... ” Some members seem particularly interesting as saxagliptin (? potent) and alogliptin (long acting… ? Better affecting fasting glucose).

Source : http://www.bibalex.org/diabetessupercourse/DiabetesPPTLectures/Copy%20of%20Incretin%20Based%20Therapy%20of%20Type%202%20Diabetes%20Mellitus_1.ppt

Slide 1 PPT

Presentation Summary : Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a ...

Source : http://www.sagarhospitals.in/Uploads/SectionContent/Case%20Study/Ocean%20OF%20Affection/Onglyza%20CME_endo.ppt

Saxagliptin Assessment of Vascular Outcomes Recorded in ... PPT

Presentation Summary : Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR) – TIMI 53 Last modified by: Bhatt, Deepak L.,M.D.,M.P.H.

Source : http://cardiometabolic.cardiosource.org/~/media/CardioMetabolic/Images/HTOct13_SAVOR_Slide2.ashx

Now or Never: The Cardiologist’s Role in Improving CV ... PPT

Presentation Summary : ... Severe Hypoglycemia and Outcome ORIGIN: Median Fasting Plasma Glucose Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with DM: ...

Source : http://img.medscape.com/images/812/739/812739_slides.ppt

HypoglycemIa Prevention + Treatment PPT

Presentation Summary : ... 10% TZDs Pio/Rosiglitazone 0% Glucosidase Inhibitor Acarbose/Miglitol 0% DPP-4 Inhibitors Sitagliptin 1% Saxagliptin 3% Amylin Pramlintide 17% Ann Intern ...

Source : http://www.childrenwithdiabetes.com/presentations/201207-FFLOrlando/Gary%20Scheiner%20Hypoglycemia%20presentation.ppt

American Diabetes Association - DiabetesPro - Home - American ... PPT

Presentation Summary : standards of medical care in diabetes—2012

Source : http://professional.diabetes.org/SlideLibrary/media/4839/ADA%20Standards%20of%20Medical%20Care%202012%20FINAL.ppt

Slide 1 PPT

Presentation Summary : ... Multiple targets may lead to unwanted effects on immune function Possible safety issues Vildagliptin, sitagliptin, and saxagliptin Pharmacologic Agents ...

Source : http://sciotocountymedicalsociety.org/documents/Current.Therapy.GLP-1.Sherraden.ppt

Download - U S Food and Drug Administration Home Page PPT

Presentation Summary : Saxagliptin n/a n/a Ofatumumab rapidly metabolized by hydrolyis of ester linkage; carboxylic acid metabolims further metabolized by glucorondination or oxidation

Source : http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/WomensHealthResearch/UCM272709.ppt

Type 2 Diabetes Management Goals PPT

Presentation Summary : Saxagliptin. Onglyza. Sitagliptin. Januvia. Dopamine-2 agonist. Activates dopaminergic receptors. Bromocriptine. Cycloset. HGP, hepatic glucose production. Inzucchi ...

Source : http://outpatient.aace.com/sites/all/files/T2DM-S5-Treatment-051713.pptx

Slide 1 PPT

Presentation Summary : Rosenstock J, et al. Curr Med Res Opin 2009;25(10):2401-11 Saxagliptin (Onglyza®) SAX/MET vs monotherapy (n=1306) Duration: 24 weeks SAX 5 mg/MET: ...

Source : http://www.wcapn.org/doc/DPP4_presentation.ppt

Is Venlafaxine ER An Effective Treatment for Posttraumatic ... PPT

Presentation Summary : ... Saxagliptin (Onglyza®) Mechanism of action Inhibit breakdown of GLP-1 and GIP Hence, levels of GLP-1 and GIP rise, especially in response to meals This ...

Source : http://health.utah.gov/diabetes/pdf/telehlth/presentation_aug10_medications.ppt

PowerPoint Presentation PPT

Presentation Summary : Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a ...

Source : http://cmcendovellore.org/DFID%20PPT%20Jan%202011/17.%20Oral%20Hypoglycemic%20Agents.ppt

Assessing Cardiovascular Risks in Diabetes: PPT

Presentation Summary : SAVOR-TIMI 53 vs Saxagliptin Phase 2 and 3. Why the Discrepancy? Meta-analysis: Improved Glucose Reduction in Macrovascular Events. Early vs Late Intervention in T2D.

Source : http://img.medscape.com/images/813/493/813493_slides.pptx

TMA DoD Pharmacoeconomic Center Fort Sam Houston, TX PPT

Presentation Summary : ... * Sitagliptin and saxagliptin have similar A1c lowering effect when used as monotherapy ~0.4-0.79% Saxagliptin/metformin FDC provides a 2.5% decrease in A1c ...

Source : http://pec.ha.osd.mil/files/WebcastPECSep11.ppt

Présentation PowerPoint - Cardiotimes PPT

Presentation Summary : ... double blind and randomized Treatment Saxagliptin vs placebo in addition to existing antihyperglycemic therapy Alogliptin vs placebo in addition to existing ...

Source : http://www.cardiotimes.com/documents/powerpoints/SLI064.ppt

Managing Diabetes in Long Term care - Centenary After Hours ... PPT

Presentation Summary : ... with a GFR of 45 mL/min, caution is required with metformin, exenatide, glybiride and saxagliptin, while sitagliptin and liraglutide are not recommended.

Source : http://www.centenaryafterhoursclinic.com/events/DM_Geriatrics_Dr_Zahedi_Nov_10_2012.ppt

Antidiabetic Medications - University of Washington PPT

Presentation Summary : ... 100 mg tablets Sitagliptin/metformin (Janumet) 50/500, 50/1000 mg tablets Saxagliptin (Onglyza) 2.5, 5 mg tablets Saxagliptin/metformin (Kombiglyze XR) ...

Source : http://courses.washington.edu/pharm585/Antidiabetic%20Medications.ppt

Sitagliptin/Metformin Clinical Slide Kit PPT

Presentation Summary : Augeri DJ, Robl JA, Betebenner DA, et al. Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, ...

Source : http://josephinecarlosraboca.weebly.com/uploads/5/0/2/2/5022425/januvia-janumet_june_24_2010.ppt_final.ppt

Slide 1 PPT

Presentation Summary : SAVOR-TIMI 53 Trial design: Patients with type 2 diabetes mellitus (DM2) and established CV disease or multiple risk factors were randomized to either saxagliptin 5 ...

Source : http://cardiometabolic.cardiosource.org/~/media/CardioMetabolic/Images/HTOct13_SAVORTIMI53_Slide1.ashx

Diabetes Case Studies - University of North Dakota PPT

Presentation Summary : Gliptin (sitagliptin or saxagliptin) Both have low risk of significant hypoglycemia, can be renally dosed, easy to use, few significant drug interactions. Brosseau JD.

Source : http://www.med.und.edu/familymedicine/slidedecks/documents/DiabetesCaseStudiesPA5-25-11.pptx

PowerPoint Presentation PPT

Presentation Summary : Title: PowerPoint Presentation Last modified by: Benedikte Created Date: 12/21/2004 9:07:39 PM Document presentation format: On-screen Show Company

Source : http://www.novonordisk.com/images/investors/investor_presentations/2005/SG%20Cowen%20CKA03082005.ppt

Dia 1 - Cardiovasculaire Geneeskunde PPT

Presentation Summary : SAVOR-TIMI 53: Saxagliptin does not affect incidence of primary end point in patientswith T2DM. Scirica. et al., NEJM 2013

Source : http://www.cvgk.nl/bestanden/246c8635149438856515000-Scririca-SAVOR-TIMI-2013-cvgk.pptx

Sponsored Links
If you find powerpoint presentation a copyright It is important to understand and respect the copyright rules of the author.
Please do not download if you find presentation copyright.
If you find a presentation that is using one of your presentation without permission, contact us immidiately at

© XPowerPoint.com